PBM Stock Summary and Trading Ideas (Psyence Biomedical Ltd. - Common Shares | NASDAQ:PBM)

Psyence Biomedical Ltd is a life science biotechnology company pioneering the use of natural psychedelics in mental health and wellbeing. It develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The company has commenced the clinical trial process to evaluate the safety and efficacy of its product candidates. It cultivates natural psilocybin mushrooms at its federally licensed facility in Southern Africa. This product is produced for export to its partners across the world to be processed into a standardized encapsulated product.

Psyence Biomedical Ltd. - Common Shares trades on the NASDAQ stock market under the symbol PBM.

As of July 2, 2026, PBM stock price declined to $3.04 with 35,163 million shares trading.

PBM has a beta of 10.23, meaning it tends to be more sensitive to market movements. PBM has a correlation of 0.18 to the broad based SPY ETF.

PBM has a market cap of $11.60 million. This is considered a Sub-Micro Cap stock.

PBM has underperformed the market in the last year with a price return of -98.6% while the SPY ETF gained +21.3%. However, in the short term, PBM had mixed performance relative to the market. It has outperformed in the last 3 months, returning +23.1% vs +13.9% return in SPY. But in the last 2 weeks, PBM shares have been beat by the market, returning -3.5% compared to an SPY return of -0.3%.

PBM support price is $2.91 and resistance is $3.31 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PBM shares will trade within this expected range on the day.